Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 35kWORD 17k
3 February 2021
P-000053/2021(ASW)
Answer given by Ms Kyriakides
on behalf of the European Commission
Question reference: P-000053/2021

1. New COVID-19 vaccines are likely to form a central part of our exit from the COVID-19 pandemic. To secure such vaccines to all EU Member States as soon as they become available, and at the same time, the Commission developed the EU Strategy for COVID-19 vaccines(1). As indicated in the strategy, a common approach would allow for e.g. sharing of risks, pooling of investments and economies of scale. After an important ground work done by France, Germany, Italy and the Netherlands, Member States endorsed the approach(2), mandating the Commission to negotiate with vaccine manufacturers while themselves remaining the ultimate acquirers of the vaccines.

2. As indicated above, an important ground work had been done by France, Germany, Italy and the Netherlands, forming an Inclusive Vaccine Alliance. The Alliance aimed to pool the national resources of the four countries and ensure fair access to COVID-19 vaccines for the European population.

3. The Commission is not in a position to comment on contracts that the Inclusive Vaccine Alliance might have negotiated before the development of the strategy.

(1)https://ec.europa.eu/commission/presscorner/detail/en/qanda_20_1662
(2)https://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1597339415327&uri=CELEX%3A52020DC0245
Last updated: 5 February 2021Legal notice - Privacy policy